FDA
-
-
-
-
-
-
-
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
-
-
-
-
-
-
-
DBV Technologies S.A (DBVT) PT Raised to $7 at H.C. Wainwright
-
-
-
-
-
-
-
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
-
-
-
-
-
-
-
Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space
-
-
-
-
-
-
-
DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results
-
-
-
-
-
-
-
DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments
-
-
-
-
-
-
-
DBV Technologies (DBVT) Announces Filing and Validation of MAA for Viaskin Peanut by EMA
-
326,554 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

